Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with
checkpoint inhibitors is still not very clear. We utilize single-cell RNA-and ATAC-sequencing …

Anti–programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to
patients with advanced melanoma. The composition of the gut microbiota correlates with anti …

Severe immune-related adverse events (irAEs) occur in up to 60% of patients with
melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Immune checkpoint blockade has provided a paradigm shift in cancer therapy, but the
success of this approach is very variable; therefore, biomarkers predictive of clinical efficacy …

Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …

The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …